Orpharma
A ray of hope
Media / News

Media and News

News

Melbourne, Australia. 31 May 2017: The Therapeutic Goods Administration in Australia approved PHEBURANE sodium phenylbutyrate granules for the management of hyperammonaemia associated with urea cycle disorders. 

 

Melbourne, Australia. 17 November 2016: Orpharma signs a distribution agreement with Cycle Pharmaceuticals for an orphan drug developed for the treatment of a metabolic condition. Orpharma has the marketing rights to the products in Australia and New Zealand.

 

Melbourne, Australia. 18 October 2016: The Therapeutic Goods Administration orphan designated carglumic acid tablets for the treatment of hyperammonaemia associated with NAGS deficiency and organic acidaemias.

 

Melbourne, Australia. 1 October 2016: Orpharma expanded its partnership with Lucane Pharma by adding more products for the treatment of various metabolic products

 

Melbourne, Australia. 1 July 2016: Orpharma launches PKU Baby and PKU Go for the dietary management of phenylketonuria.

 

Melbourne, Australia. 1 April 2016: Orpharma launches PKU Microtabs for the dietary management of phenylketonuria and Citrulline Easy tablets for the dietary management of Urea Cycle Disorders.

 

Melbourne, Australia. 1 March 2016: Orpharma launches two products for the dietary management of phenylketonuria. PKU Easy Shake & Go is available in orange flavour and PKU Easy liquid is available in berries and citrus.

 

Melbourne, Australia. 6 November 2015: Orpharma expands its partnership with POA Pharma Scandinavia AB by signing a new distribution agreement for products containing Antisecretory Factor. The products were developed to treat Crohn’s disease, short bowel syndrome and Meniere’s disease.

 

Melbourne, Australia. October 29, 2015: PHEBURANE approved for treatment of Urea Cycle Disorders by MEDSAFE in New Zealand with provisional listing agreement signed with PHARMAC.

 

Melbourne, Australia. July 03, 2015: Orpharma signed a distribution agreement with POA Pharma Scandinavia for a range of niche age-specific medical nutrition products developed for patients suffering from metabolic conditions. Orpharma has the marketing rights to the products in multiple markets.

 

Melbourne, Australia. April 23, 2015: Orpharma signed a distribution agreement with Asklepion Pharmaceuticals for Citrupress, an intravenous form of the amino acid L-citrulline. Citrupress is under development for the treament of children undergoing cardiopulmonary bypass during heart surgery. Orpharma has the marketing rights for the product in multiple markets.

 

Melbourne, Australia. August, 20, 2014: Orpharma Pty Ltd submitted an application to the Therapeutic Goods Administration (TGA) in Australia seeking orphan designation of Pheburane.

The application for orphan drug designation was approved on 13 August for the treatment of urea cycle disorders

 

Melbourne, Australia. April, 15, 2014: Orpharma signed an exclusive distribution agreement for Pheburane® with Lucane Pharma, a company based in France. The agreement covers the Australian and New Zealand territories.

Pheburane is an improved formulation of sodium phenylbutyrate developed for the treatment of Urea Cycle Disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase and argininosuccinate synthetase.

 

Melbourne, Australia. July 25, 2013: Orpharma Pty Ltd submitted an application to the Therapeutic Goods Administration (TGA) in Australia to have Cholic acid capsules designated as an orphan drug.

The application for orphan drug designation was approved on 23 July for the treatment of inborn errors of bile acid synthesis responsive to treatment with cholic acid.

 

Melbourne, Australia. May 31, 2013: Orpharma signed a distribution deal with Neolutions for a range of niche products. Orpharma has the marketing rights to these products in Australia, New Zealand and South East Asia.

 

Articles/Papers

If you would like more information on our products, please send a request to enquiries@orpharma.com.